Dr Reddy’s Laboratories on Friday reported a 21 per cent year-on-year rise in consolidated net profit to Rs 1,587 crore for the quarter ended March 2025, buoyed by robust sales across key markets including the US and India.The Hyderabad-basedpharmaceutical firm had posted a net profit of Rs 1,307 crore in the same quarter last year.Revenue for the January–March quarter climbed to Rs 8,506 crore, up from Rs 7,083 crore a year earlier, the company said in a regulatory filing.For the full financial year 2024-25, Dr Reddy’s posted a net profit of Rs 5,724 crore, reflecting a modest 3 per cent growth over Rs 5,568 crore recorded in FY24. Annual revenue rose to Rs 32,553 crore from Rs 27,916 crore in the previous fiscal.“We achieved double-digit growth across our businesses, driven by successful product launches, increased revenues from key products in the US, and the integration of the acquired NRT business,” said G V Prasad, Co-Chairman and Managing Director of Dr Reddy’s Laboratories.He added that the company remains focused on strengthening core operations through portfolio management, operational excellence, and strategic partnerships, including potential acquisitions.In FY25, North American revenue grew 12 per cent to Rs 14,516 crore from Rs 12,989 crore in FY24. Revenue from India’s generics segment rose 16 per cent to Rs 5,373 crore from Rs 4,641 crore.The board has recommended a final dividend of Rs 8 per equity share of Re 1 for FY25. It also approved the reappointment of G V Prasad as Whole-Time Director designated as Co-Chairman and Managing Director for a five-year term from January 30, 2026, to January 29, 2031.Shares of Dr Reddy’s ended 0.67 per cent higher at Rs 1,156.40 on the BSE.
